Stephens Inc. AR Grows Stock Holdings in Boston Scientific Corporation $BSX

Stephens Inc. AR raised its position in Boston Scientific Corporation (NYSE:BSX) by 10.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,846 shares of the medical equipment provider’s stock after acquiring an additional 1,046 shares during the quarter. Stephens Inc. AR’s holdings in Boston Scientific were worth $1,165,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. 1248 Management LLC purchased a new position in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter valued at about $27,000. Sound Income Strategies LLC increased its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific during the second quarter valued at about $37,000. Finally, Activest Wealth Management increased its position in shares of Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 over the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Down 1.4%

NYSE:BSX opened at $102.42 on Friday. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company’s 50-day simple moving average is $101.18 and its 200 day simple moving average is $101.92. The firm has a market capitalization of $151.75 billion, a P/E ratio of 54.77, a PEG ratio of 2.45 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of several research analyst reports. BTIG Research reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Wednesday. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.